Mapp Biopharmaceutical infectious news

Mapp is increasing production of its ZMapp Ebola treatment “as quickly as possible” after reports of the compound’s efficacy in two Americans infected in Liberia. Mapp said in a statement that the preclinical product consists of mAbs manufactured in the Nicotiana plant, and that “very little of the drug is currently available.” According to media reports, ZMapp was given to the patients seven to 10 days after virus exposure and led to significant improvements in both.

FDA declined to disclose whether it issued an emergency IND for ZMapp, but Mapp said in its statement that any use of the compound “would be a decision made by the treating physician under the regulatory guidelines of the FDA.” ...